Premium
Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin
Author(s) -
Namba Chika,
Tohyama Mikiko,
Hanakawa Yasushi,
Murakami Masamoto,
Shirakata Yuji,
Matsumoto Takuya,
Suemori Koichiro,
Ishii Norito,
Hashimoto Takashi,
Sayama Koji
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13160
Subject(s) - bronchiolitis obliterans , rituximab , medicine , intravenous immunoglobulins , antibody , pemphigus , immunology , paraneoplastic pemphigus , bronchiolitis , gastroenterology , lung , autoantibody , lung transplantation , virus
Paraneoplastic pemphigus ( PNP ) is an autoimmune blistering disease that presents as severe mucosal erosions and variable cutaneous lesions and is primarily associated with hematologically malignant or benign diseases. A 59‐year‐old Japanese woman presented with oral, ocular and vaginal mucosal erosions and erythema as well as blistering on her trunk and limbs. She developed bronchiolitis obliterans; lymphadenopathy in the cervical, subclavian, para‐aortic and intraperitoneal regions; and splenomegaly. PNP with B‐cell lymphoma was diagnosed. She was treated with two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‐CHOP) for B‐cell lymphoma, rituximab once every 3 weeks for five cycles, steroid pulse therapy, oral prednisolone, cyclosporin and high‐dose i.v. immunoglobulin. The B‐cell lymphoma was in remission after two courses of R‐ CHOP treatment. Although her skin erythema and blistering were also improved, the mucosal erosions and bronchiolitis obliterans gradually worsened. The patient died of bronchiolitis obliterans after 6 months of hospitalization. Because a cellular immune response is thought to be involved in the pathogenesis of PNP , cyclosporin therapy is expected to aid in suppressing the cellular response. In this case, however, the patient's mucosal lesions and bronchiolitis obliterans were not improved by regular administration of cyclosporin therapy.